Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Johnson & Johnson: 4Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
01/22/2020 | 07:43am EDT

NEW BRUNSWICK, N.J. (AP) _ Johnson & Johnson (JNJ) on Wednesday reported fourth-quarter earnings of $4.01 billion.

On a per-share basis, the New Brunswick, New Jersey-based company said it had profit of $1.50. Earnings, adjusted for one-time gains and costs, were $1.88 per share.

The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $1.86 per share.

The world's biggest maker of health care products posted revenue of $20.75 billion in the period, which missed Street forecasts. Four analysts surveyed by Zacks expected $20.79 billion.

Johnson & Johnson expects full-year earnings in the range of $8.95 to $9.10 per share, with revenue in the range of $85.4 billion to $86.2 billion.

Johnson & Johnson shares have increased slightly more than 2% since the beginning of the year, while the Standard & Poor's 500 index has climbed almost 3%. The stock has increased 14% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on JNJ at https://www.zacks.com/ap/JNJ

© 2020 The Canadian Press. All rights reserved., source Canadian Press DataFile


share with twitter share with LinkedIn share with facebook
All news about JOHNSON & JOHNSON
03:01aKARO PHARMA : publishes third-quarter report 2020 and resolves on sale of own sh..
AQ
10/28Combined Market Cap of Five Largest MedTech Companies Surged by $40bn YoY
AQ
10/28JOHNSON & JOHNSON : Thinking about trading options or stock in Microsoft, First ..
PR
10/27JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA for New Indication t..
AQ
10/27JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA for New Indication t..
AQ
10/26WALL STREET STOCK EXCHANGE : US companies under China sanctions, Many acquisitio..
10/26JOHNSON & JOHNSON : Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COV..
AQ
10/24AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to..
RE
10/23JOHNSON & JOHNSON : Pivotal Study of J&J's Covid-19 Vaccine to Resume, Company S..
DJ
10/23JOHNSON & JOHNSON : Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COV..
PU
More news
Financials (USD)
Sales 2020 81 814 M - -
Net income 2020 15 967 M - -
Net Debt 2020 7 344 M - -
P/E ratio 2020 22,6x
Yield 2020 2,90%
Capitalization 361 B 361 B -
EV / Sales 2020 4,50x
EV / Sales 2021 4,09x
Nbr of Employees 132 200
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 165,22 $
Last Close Price 137,19 $
Spread / Highest target 31,2%
Spread / Average Target 20,4%
Spread / Lowest Target 1,32%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-5.95%361 159
ROCHE HOLDING AG-6.40%274 461
PFIZER INC.-9.95%196 047
MERCK & CO., INC.-16.56%191 944
NOVARTIS AG-22.62%176 518
NOVO NORDISK A/S9.93%154 639